Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARTRUVO vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Olaratumab is a recombinant human Ig G1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery, in combination with doxorubicin.
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life is approximately 11 days (range 4–20 days), supporting a 3-week dosing interval when combined with doxorubicin.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Olaratumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways identified.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Olaratumab is cleared primarily via proteolytic catabolism; no specific renal or biliary excretion studies have been conducted. In patients, only trace amounts are excreted in urine (<1% of dose).
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Approximately 90% bound to plasma proteins (primarily Ig G, as a monoclonal antibody).
47% bound to plasma proteins (primarily albumin)
Central volume of distribution is approximately 4.1 L (0.058 L/kg for a 70 kg patient), indicating limited extravascular distribution, consistent with a large monoclonal antibody.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
100% (intravenous administration only; not bioavailable orally).
IV: 100% (only IV route); oral: not approved
No dose adjustment required for mild to moderate renal impairment (CLcr 30-89 m L/min). Not studied in severe renal impairment (CLcr <30 m L/min) or end-stage renal disease; use only if benefit outweighs risk.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate or severe (Child-Pugh B or C): not studied; use only if benefit outweighs risk.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and efficacy not established in pediatric patients; no recommended dose.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No dose adjustment based on age; monitor for adverse reactions more frequently due to higher incidence of underlying renal or hepatic impairment and comorbidities.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
WARNING: INFUSION-RELATED REACTIONS (IRRs), INCLUDING DEATH. Serious and sometimes fatal infusion-related reactions can occur. Premedicate and monitor during infusion. Interrupt or permanently discontinue based on severity.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Infusion-related reactions (including severe and fatal); embryo-fetal toxicity; neutropenia; cardiotoxicity (left ventricular dysfunction); and increased adverse reactions in patients with baseline left ventricular ejection fraction (LVEF) below normal.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
None known.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions known. However, doxorubicin may cause nausea and vomiting; advise taking antiemetics as prescribed and eating small, frequent meals. Avoid grapefruit and grapefruit juice as they may affect CYP3A4 metabolism of doxorubicin.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Based on its mechanism of action (PDGFR-alpha inhibitor) and animal studies, LARTRUVO (olaratumab) is expected to cause fetal harm when administered to pregnant women. There are no adequate human data. In animal reproduction studies, administration of olaratumab to pregnant monkeys during organogenesis resulted in embryofetal toxicity including increased abortion and fetal anomalies. Use is contraindicated in pregnancy; advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose. Risks apply throughout all trimesters.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
No data on the presence of olaratumab in human milk, effects on the breastfed infant, or milk production. Due to the potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
LARTRUVO is contraindicated in pregnancy. No dose adjustments during pregnancy have been studied. Pharmacokinetics may alter due to pregnancy-induced changes in volume of distribution, protein binding, and clearance; however, no specific dose adjustment guidelines exist. If treatment is absolutely necessary in a pregnant patient (which is not recommended), consider therapeutic drug monitoring if feasible.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
LARTRUVO (olaratumab) is a PDGFRα inhibitor used in combination with doxorubicin for advanced soft tissue sarcoma not amenable to surgery or radiotherapy. Monitor for infusion-related reactions and pre-medicate with antihistamines and corticosteroids. Assess cardiac function via echocardiogram or MUGA scan before each cycle due to doxorubicin cardiotoxicity. Neutropenia is common; monitor CBCs before each cycle and hold for ANC <1000/mm3. Olaratumab does not require dose adjustment for mild to moderate hepatic impairment but avoid in severe impairment. No dose adjustment for renal impairment. Pregnancy category D: advise effective contraception during and for 3 months after treatment.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
This medication is given as an intravenous infusion over 60 minutes on Day 1 and Day 8 of each 21-day cycle.,You will receive it together with another chemotherapy drug called doxorubicin.,Common side effects include nausea, fatigue, low white blood cell counts, and infusion-related reactions (fever, chills, shortness of breath).,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising immediately.,Avoid pregnancy and breastfeeding while on this treatment; use effective birth control during and for 3 months after the last dose.,Do not take any other medications, supplements, or herbal products without consulting your doctor.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARTRUVO vs CLOFARABINE, answered by our medical review team.
LARTRUVO is a Antineoplastic Agent that works by Olaratumab is a recombinant human Ig G1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARTRUVO and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARTRUVO is: 10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARTRUVO and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARTRUVO is classified as Category C. Based on its mechanism of action (PDGFR-alpha inhibitor) and animal studies, LARTRUVO (olaratumab) is expected to cause fetal harm when administered to pregnant women. There are no. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.